Frontier Pharma - Rheumatoid Arthritis: Industry Analysis Report

GBI Research has released a new pharmaceutical report, “Frontier Pharma: Rheumatoid Arthritis Identifying and Commercializing First-in-Class Innovation&rd stages. These new developments are driven by improvements in the understanding of signaling pathways and underlying disease mechanisms of Rheumatoid Arthritis (R The market is also characterized by high activity in licensing and co-development deals. In particular, there is sustained commercial interest in pipeline biologic therapie Scope The report analyzes the RA pipeline and strategic alliance landscape with particular emphasis on first-in-class programs. A brief introduction to RA, including symptom molecular targets highlighting early-stage programs with clinical utility that has yet to be evaluated, as well as an in-depth literature review of novel molecular targets As Reasons to buy The report will assist business development strategies of companies who wish to develop RA therapies with improved benefits to existing treatments. In addition, this r model data Assess the value of products benchmarked against licensed and co-developed therapeutic programs Spot first-in-class programs that are potentially available

table Of Contents

1 Table Of Contents 1 Table Of Contents 5 1.1 List Of Tables 6 1.2 List Of Figures 7

2 Introduction 8 2.1 The Case For Innovation 8 2.1.1 Growing Opportunities For Biologic Products 8 2.1.2 Diversification Of Molecular Targets 8 2.1.3 Innovative First-in-class Product Developments Remain Attractive 9 2.1.4 Changes In The Clinical And Commercial Environment To Be More Favorable To Products Targeting Niche Patient Populations And Niche Indications 9 2.1.5 Sustained Innovation 10

3 Clinical And Commercial Landscape 11 3.1 Disease Overview 11 3.1.1 Disease Symptoms 12 3.1.2 Environmental Factors And Genetic Predisposition 12 3.1.3 Disease Pathophysiology 12 3.1.4 Pharmacotherapy Algorithm 13 3.2 Overview Of Marketed Products For Rheumatoid Arthritis 14 3.3 Molecular...